Fate Therapeutics Highlights Autoimmune CAR-T Potential at Cantor Conference

Fate Therapeutics presented its autoimmune-focused CAR-T programs at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, emphasizing advancements in precision manufacturing and clinical efficacy for conditions like lupus nephritis and systemic sclerosis. The company’s lead candidate, FT819, targets CD19 in the TRAC locus to treat lupus nephritis, with a planned Phase II single-arm study enrolling up to 53 patients. First dosing began in August 2024, with the primary endpoint—complete renal response (CRR) at six months—targeting a 30% to 40% efficacy rate, compared to historical controls of 10% to 20%. Enrollment is expected to wrap within 18 months of study initiation, with interim data due in the second half of 2025 and full results projected by 2028, followed by a Biologics License Application (BLA) submission. FT819’s manufacturing process leverages a master cell bank capable of producing over 10 million doses per batch, reducing variability to a uniform genetic edit—13 points—unlike traditional autologous or allogeneic systems, which produce fewer than 500 doses per donor T-cell source. This approach has delivered more than 1 gram per gram reductions in urinary protein-to-creatinine ratio (UPCR) at six months, with a bendamustine-enriched cohort showing 1.8 grams per gram reductions. In a no-conditioning cohort at dose level 1, three of three patients achieved sustained response indicator 4 (SRI4), and two of three reached low disease activity state (LLDAS). CEO Bob noted FT819’s potency, calling it the most potent CAR-T in development, and its regulatory appeal for its safety-focused design. Meanwhile, FT839—a dual-target CAR-T combining CD19 and CD38—received an Investigational New Drug (IND) clearance within 30 days, with first patient dosing expected within months. The CD38 target engages activated immune cells (10%-15% of the immune system), preserving the remaining 85% of the system. Fate’s 40,000-square-foot facility supports 50,000 doses annually, further underscoring its manufacturing scalability. The company’s programs also benefit from regulatory designations, including a Rare Medical Condition (RMAT) designation for FT819 and inclusion in the FDA’s Cell and Gene Therapy Program (CDRP).